Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles

Cornea

Volumn 29, Issue 5, 2010, Pages 550-558

  Contreras Ruiz, Laura ^a,b   De La Fuente, María ^c   García Vázquez, Carmen ^a,b   Sáez, Victoria ^a,b   Seijo, Begoña ^c   Alonso, María J ^c   Calonge, Margarita ^a,b   Diebold, Yolanda ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chitosan; Drug delivery; Epithelial cell; Hyaluronic acidchitosan nanoparticles

Indexed keywords

BUFFER; FLUORESCEINAMINE; FLUORESCENT DYE; HYALURONIC ACID CHITOSAN NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INSTILLATION; DRUG TOLERABILITY; DRUG UPTAKE; EXPERIMENTAL MODEL; EYE DISCOMFORT; EYE IRRITATION; FEMALE; FLUORESCENCE; GELATION; HISTOPATHOLOGY; IN VIVO STUDY; LACRIMAL APPARATUS; LACRIMATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; TEAR FILM;

ANIMALS; CHITOSAN; CONJUNCTIVA; CORNEA; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; FEMALE; FLUORESCAMINE; HYALURONIC ACID; LACRIMAL APPARATUS; NANOPARTICLES; OPHTHALMIC SOLUTIONS; RABBITS; TEARS;

EID: 77951768401     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181bd9eee     Document Type: Article

References (36)

1. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother. 2004;58:168-172.
2. Klausner EA, Peer D, Chapman RL, et al. Corneal gene therapy. J Control Release. 2007;124:107-133.
3. Liu X, Brandt CR, Rasmussen CA, et al. Ocular drug delivery: molecules, cells, and genes. Can J Ophthalmol. 2007;42:447-454.
4. Calvo P, Thomas C, Alonso MJ, et al. Study of the mechanism of interaction of poly-e-caprolactone nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm. 1994;103:283-291.
5. De Campos AM, Diebold Y, Carvalho EL, et al. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21:803-810.
6. De la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular and transfect ocular tissue. Gene Ther. 2008;15:668-676.
7. Losa C, Alonso MJ, Vila-Jato JL, et al. Reduction of cardiovascular size effects associated with ocular administration of metipranolol by inclusion in polymeric nanocapsules. J Ocul Pharmacol Ther. 1992;8: 191-198.
8. De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159-168.
9. De Campos AM, Sánchez A, Gref R, et al. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci. 2003;20:73-81.
10. Enriquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47:1416-1425.
11. Eliaz RE, Szoka FC. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001;6:2592-2601.
12. Lerner LE, Schwartz DM, Hwang DG, et al. Hyaluronan and CD44 in the human cornea and conjunctiva. Exp Eye Res. 1998;67:481-484.
13. Zhu SN, Nö lle B, Duncker BG, et al. Expression of adhesion molecule CD44 in human corneas. Br J Ophthalmol. 1997;81:80-84.
14. De la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci. 2008;49: 2016-2024.
15. Menzel EJ, Farr C. Hyaluronidase and its substrate hyaluronate: biochemistry, biological activities and therapeutic uses. Cancer Lett. 1998;131:3-11.
16. Aragona P. Hyaluronan in the treatment of ocular surface disorders. In: Garga HG, Hales CA, eds. Chemistry and Biology of Hyaluronan. Oxford, United Kingdom: Elsevier Ltd; 2004:529-551.
17. Greaves JL, Wilson CG. Treatment of diseases of the eye with mucoadhesive delivery systems. Adv Drug Deliv Rev. 1993;11:349-383.
18. Kyyronen K, Hume L, Urtti A, et al. Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release studies. Int J Pharm. 1992;80:161-169.
19. Yerushalmi N, Margalit R. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch Biochem Biophys. 1998;349: 21-26.
20. Barbault-Foucher S, Gref R, Russo P, et al. Design of poly-e-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J Control Release. 2002;83:365-375.
21. Hornof M, De la Fuente M, Hallikainen M, et al. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. J Gene Med. 2008;10: 70-80.
22. De la Fuente M, Seijo B, Alonso MJ. Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules. Macromol Biosci. 2008;8:441-450.
23. De la Fuente M, Seijo B, Alonso MJ. Design of novel polysaccharidic nanostructures for gene delivery. Nanotechnology. 2008;3:845-857.
24. De Belder AN,Wik KO. Preparation and properties of fluorescein-labelled hyaluronate. Carbohydr Res. 1975;44:251-257.
25. Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41-50. (Pubitemid 27283332)
26. Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposomechitosan nanoparticle complexes (LCS-NP). Biomaterials. 2007;28: 1553-1564.
27. Calonge M, Diebold Y, Sáez V, et al. Impression cytology of the ocular surface: a review. Exp Eye Res. 2004;78:457-472.
28. Nelson JD. Impression cytology. Cornea. 1988;7:71-81.
29. Sánchez A, Alonso MJ. Nanoparticular carriers for ocular drug delivery. In: Torchilin VP, ed. Nanoparticulates as Drug Carriers. Imperial College Press: London, United Kingdom; 2006:649. ISBN 1-86094-630-5.
30. Calvo P, Alonso MJ, Vila-Jato JL, et al. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol. 1996; 48:1147-1152.
31. Desai MP, Labhasetwar V, Amidon G, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13: 1838-1845.
32. Jani PU, Halbert GW, Langridge J, et al. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990;42:821-826.
33. Cortesi R, Argnani R, Esposito E, et al. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int J Pharm. 2006;317:90-100.
34. Kompella UB, Katragadda AK, Aukunuru JV, et al. Effect of liposomal charge on stavudine transport across rabbit cornea and conjunctiva. Pharm Pharmacol Commun. 1998;4:339-343.
35. Sussman JD, Friedman MP. Irritation of rabbit eye caused by contact lens wetting solutions. Am J Ophthalmol. 1969;68:703-706.
36. Griffith JF, Nixon GA, Bruce RD, et al. Dose-response studies with chemical irritants in the albino rabbit eye as a basis for selecting optimum testing conditions for predicting hazard to the human eye. Toxicol Appl Pharmacol. 1980;55:501-513.